In a recent filing, Jonathan P. DiVincenzo, President and COO of Bio-Rad Laboratories, Inc., has reported the acquisition of shares through restricted stock units. This transaction, which took place on October 24, 2026, underscores DiVincenzo's ongoing commitment to the company and may have implications for investor confidence in Bio-Rad.

DiVincenzo acquired a total of 1,869 shares of Bio-Rad A Common Stock as part of his compensation package. Additionally, he purchased 951 shares at a price of $369.95 each. Following these transactions, DiVincenzo now owns a total of 3,832 shares of the company's stock.

Background

Bio-Rad Laboratories, Inc. is a leading company in the laboratory analytical instruments sector, specifically classified under the SIC code 3826. The company is incorporated in Delaware and is headquartered in Hercules, California. Bio-Rad is known for its innovative products and services that cater to the life sciences and clinical diagnostics markets.

Recent filings show that DiVincenzo has been active in managing his stock holdings, with several Form 4 filings in the past year. This latest filing, accession number 0000012208-26-000050, was submitted on October 27, 2026, and reflects transactions that occurred just a few days prior.

What the Filing Says

The filing indicates that DiVincenzo's transactions included:

"Shares of Class A common stock acquired on the vesting of restricted stock units."

Additionally, it notes that each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock, vesting over four years at a rate of 25% per year on the anniversary date of the grant.

Impact

This move may affect investor sentiment towards Bio-Rad, as executive stock purchases are often viewed positively by the market. DiVincenzo's role as President and COO positions him as a key figure in the company's strategic direction, and his investment in the company could signal confidence in its future performance.

What's Next

The filing does not say what happens next.